Tempus AI Acquires Paige to Enhance Digital Pathology and Advance Precision Medicine
I'm PortAI, I can summarize articles.
Tempus AI, Inc. has acquired Paige, an AI company in digital pathology, for $81.25 million. This acquisition aims to enhance Tempus's dataset and technical team, strengthening its position in digital pathology. The deal primarily involves payment in Tempus common stock and includes Paige's cloud services agreement with Microsoft Azure. Paige's collaboration with Memorial Sloan Kettering Cancer Center provides valuable data, expected to accelerate Tempus's oncology model development.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments